908 Devices Inc. (MASS) Financial Statements
908 Devices Inc. (MASS) reported trailing twelve-month revenue of $60.8M (up 13.4% year on year) and net income of -$34.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $615000.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MASS908 Devices Inc.Follow MASS — free
—
Price chart with a free account
- Market cap
- 474.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 42.2 | 46.9 | 50.2 | 47.7 | 56.2 | 60.8 | |
| Gross profit | 23.2 | 26.0 | 25.3 | 24.5 | 28.4 | 31.7 | |
| Research & development | 13.1 | 17.5 | 21.9 | 15.0 | 15.6 | 14.4 | |
| Operating income | -22.1 | -35.4 | -42.8 | -57.4 | -39.4 | -38.9 | |
| Pre-tax income | — | -33.6 | -36.6 | -53.1 | -33.3 | -34.6 | |
| Income tax | — | — | -0.2 | -0.3 | -0.1 | -0.2 | |
| Net income | -22.2 | -33.6 | -36.4 | -72.2 | 19.5 | -34.7 | |
| Diluted EPS ($) | -0.79 | -1.07 | -1.13 | -2.12 | 0.54 | -0.94 | |
| Diluted shares (mn) | 28.0 | 31.5 | 32.2 | 34.1 | 35.9 | — |
USD millions · SEC XBRL
908 Devices Inc. — questions
- What is 908 Devices Inc.'s revenue?
- $60.8M over the twelve months to 2026-06-30, up 13.4% year on year, from its 10-Q and 10-K filings.
- What is 908 Devices Inc.'s net income?
- -$34.7M over the twelve months to 2026-06-30.
- What is 908 Devices Inc.'s free cash flow?
- $615000 over the twelve months to 2026-06-30.
- What are 908 Devices Inc.'s diluted earnings per share?
- $-0.94 over the twelve months to 2026-06-30.
Every figure on this page comes from 908 Devices Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.